These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11145438)

  • 1. Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group.
    Wisløff F; Gulbrandsen N
    Acta Oncol; 2000; 39(7):809-13. PubMed ID: 11145438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group.
    Wisløff F; Hjorth M; Kaasa S; Westin J
    Br J Haematol; 1996 Aug; 94(2):324-32. PubMed ID: 8759893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group.
    Wisløff F; Eika S; Hippe E; Hjorth M; Holmberg E; Kaasa S; Palva I; Westin J
    Br J Haematol; 1996 Mar; 92(3):604-13. PubMed ID: 8616024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group.
    Wisløff F; Hjorth M
    Br J Haematol; 1997 Apr; 97(1):29-37. PubMed ID: 9136939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support.
    Gulbrandsen N; Wisløff F; Brinch L; Carlson K; Dahl IM; Gimsing P; Hippe E; Hjorth M; Knudsen LM; Lamvik J; Lenhoff S; Løfvenberg E; Nesthus I; Nielsen JL; Turesson I; Westin J;
    Med Oncol; 2001; 18(1):65-77. PubMed ID: 11778972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial.
    Delforge M; Dhawan R; Robinson D; Meunier J; Regnault A; Esseltine DL; Cakana A; van de Velde H; Richardson PG; San Miguel JF
    Eur J Haematol; 2012 Jul; 89(1):16-27. PubMed ID: 22469559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Browman GP; Bergsagel D; Sicheri D; O'Reilly S; Wilson KS; Rubin S; Belch A; Shustik C; Barr R; Walker I
    J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
    Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
    Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study.
    Cooper MR; Dear K; McIntyre OR; Ozer H; Ellerton J; Canellos G; Bernhardt B; Duggan D; Faragher D; Schiffer C
    J Clin Oncol; 1993 Jan; 11(1):155-60. PubMed ID: 8418228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
    Ludwig H; Cohen AM; Huber H; Nachbaur D; Jungi WF; Senn H; Günczler P; Schüller J; Eckhardt S; Seewann HL
    Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.
    Verelst SG; Termorshuizen F; Uyl-de Groot CA; Schaafsma MR; Ammerlaan AH; Wittebol S; Sinnige HA; Zweegman S; van Marwijk Kooy M; van der Griend R; Lokhorst HM; Sonneveld P; Wijermans PW;
    Ann Hematol; 2011 Dec; 90(12):1427-39. PubMed ID: 21472373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Cooperative Study Group.
    Westin J; Rödjer S; Turesson I; Cortelezzi A; Hjorth M; Zador G
    Br J Haematol; 1995 Mar; 89(3):561-8. PubMed ID: 7734355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melphalan/prednisone versus melphalan/prednisone plus human alpha interferon therapy in patients with multiple myeloma, stages II and III. Myeloma Group of Central Sweden.
    Björkholm M
    Eur J Cancer; 1991; 27 Suppl 4():S51-2. PubMed ID: 1799480
    [No Abstract]   [Full Text] [Related]  

  • 16. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma.
    Zee B; Cole B; Li T; Browman G; James K; Johnston D; Sugano D; Pater J
    J Clin Oncol; 1998 Aug; 16(8):2834-9. PubMed ID: 9704736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
    Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
    Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Quality of life and tolerance of maintenance therapy in patients with multiple myeloma].
    Adam Z; Pour L; Svobodník A; Scudla V; Salajka F; Vytrasová M; Bacovský J; Schützová M; Koza V; Sumná E; Franková H; Lehanka F; Gumulec J; Stavarová Y; Cahová S; Vránová M; Dostálová V; Kessler P; Walterová L; Meluzínová I; Seifertová N; Sláma O; Büchler T; Krejcí M; Bencíková V; Nykodýmová V; Dusek L; Hájek R;
    Vnitr Lek; 2002 Mar; 48(3):216-29. PubMed ID: 11968583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial.
    Seefat MR; Stege CAM; Lissenberg-Witte BI; Levin MD; Timmers GJ; Hoogendoorn M; Ypma PF; Klein SK; Velders GA; Westerman M; Strobbe L; Durdu-Rayman N; Davidis-van Schoonhoven MA; van Kampen RJW; Dijk AC; Koster A; Silbermann MH; van der Spek E; Beeker A; Erjavec Z; de Graauw NCHP; Leys MBL; Sonneveld P; van de Donk NWCJ; Nasserinejad K; Blommestein HM; Cucchi DGJ; Zweegman S
    Eur J Cancer; 2024 Aug; 207():114153. PubMed ID: 38870747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.
    Nord E; Wisløff F; Hjorth M; Westin J
    Pharmacoeconomics; 1997 Jul; 12(1):89-103. PubMed ID: 10169390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.